Biotech · Public company · San Francisco, CA, US

Kyntra Bio, Inc.

Ticker KYNB · SEC CIK 0000921299

Track this companyFree. Adds Kyntra Bio, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials253 recruiting or active

Pipeline programs26From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline26

CorticosteroidsPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
Epoetin AlfaPhase 3 · Anemia in Incident Dialysis PatientsClinicalTrials.gov · fetched Nov 12, 2026
Epoetin AlfaPhase 3 · CKD Anemia in Stable Dialysis PatientsClinicalTrials.gov · fetched Nov 12, 2026
PamrevlumabPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
PamrevlumabPhase 3 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOXPhase 3 · Pancreatic Cancer Non-resectableClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · CKD Anemia in Stable Dialysis PatientsClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · CKD AnemiaClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · Anemia in Incident Dialysis PatientsClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · Anemia Associated With End Stage Renal Disease (ESRD)ClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · Anemia Associated With End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · Anemia Associated With Chronic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 3 · Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)ClinicalTrials.gov · fetched Nov 12, 2026
Epoetin AlfaPhase 2 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
FG-3019Phase 2 · Pancreatic Cancer (Unresectable)ClinicalTrials.gov · fetched Nov 12, 2026
FG-3246Phase 2 · Metastatic Castration-Resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
GemcitabinePhase 2 · Pancreatic Cancer (Unresectable)ClinicalTrials.gov · fetched Nov 12, 2026
IV IronPhase 2 · DialysisClinicalTrials.gov · fetched Nov 12, 2026
Nab-paclitaxelPhase 2 · Pancreatic Cancer (Unresectable)ClinicalTrials.gov · fetched Nov 12, 2026
Oral IronPhase 2 · DialysisClinicalTrials.gov · fetched Nov 12, 2026
PamrevlumabPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 2 · Chronic Kidney DiseaseClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 2 · Chemotherapy Induced AnemiaClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 2 · DialysisClinicalTrials.gov · fetched Nov 12, 2026
RoxadustatPhase 2 · End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
FG-3019Phase 1 · Idiopathic Pulmonary FibrosisClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Imaging Study of [89Zr]DFO-YS5 for Cancer DetectionPHASE1 · RECRUITING · started Jun 15, 2026ClinicalTrials.gov NCT07664397 · fetched Nov 12, 2026
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)PHASE2 · RECRUITING · started Feb 22, 2026ClinicalTrials.gov NCT06842498 · fetched Nov 12, 2026
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKDPHASE3 · WITHDRAWN · started May 23, 2022ClinicalTrials.gov NCT04621331 · fetched Nov 12, 2026
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 19, 2022ClinicalTrials.gov NCT05011188 · fetched Nov 12, 2026
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDPHASE3 · TERMINATED · started Mar 3, 2021ClinicalTrials.gov NCT04632940 · fetched Nov 12, 2026
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)PHASE3 · TERMINATED · started Sep 30, 2020ClinicalTrials.gov NCT04419558 · fetched Nov 12, 2026
Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)PHASE3 · TERMINATED · started Aug 10, 2020ClinicalTrials.gov NCT04371666 · fetched Nov 12, 2026
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis ParticipantsPHASE3 · COMPLETED · started Jul 22, 2020ClinicalTrials.gov NCT04484857 · fetched Nov 12, 2026
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 DiseasePHASE2 · TERMINATED · started Jun 20, 2020ClinicalTrials.gov NCT04432298 · fetched Nov 12, 2026
Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis ParticipantsPHASE3 · COMPLETED · started May 26, 2020ClinicalTrials.gov NCT04410198 · fetched Nov 12, 2026
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaPHASE2 · COMPLETED · started Aug 20, 2019ClinicalTrials.gov NCT04076943 · fetched Nov 12, 2026
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)PHASE3 · TERMINATED · started Jun 18, 2019ClinicalTrials.gov NCT03955146 · fetched Nov 12, 2026
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic CancerPHASE3 · COMPLETED · started May 10, 2019ClinicalTrials.gov NCT03941093 · fetched Nov 12, 2026
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenPHASE3 · TERMINATED · started Jan 29, 2018ClinicalTrials.gov NCT03263091 · fetched Nov 12, 2026
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)PHASE2 · TERMINATED · started Jan 4, 2016ClinicalTrials.gov NCT02606136 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisPHASE3 · COMPLETED · started Jan 15, 2015ClinicalTrials.gov NCT02273726 · fetched Nov 12, 2026
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic CancerPHASE1_PHASE2 · COMPLETED · started Jul 31, 2014ClinicalTrials.gov NCT02210559 · fetched Nov 12, 2026
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis ParticipantsPHASE3 · COMPLETED · started Feb 11, 2014ClinicalTrials.gov NCT02052310 · fetched Nov 12, 2026
A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving DialysisPHASE3 · COMPLETED · started Nov 5, 2012ClinicalTrials.gov NCT01750190 · fetched Nov 12, 2026
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney DiseasePHASE2 · COMPLETED · started May 18, 2012ClinicalTrials.gov NCT01630889 · fetched Nov 12, 2026
Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent TreatmentPHASE2 · COMPLETED · started Jul 21, 2011ClinicalTrials.gov NCT01414075 · fetched Nov 12, 2026
Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With AnemiaPHASE2 · COMPLETED · started Oct 29, 2010ClinicalTrials.gov NCT01244763 · fetched Nov 12, 2026
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisPHASE2 · COMPLETED · started May 17, 2010ClinicalTrials.gov NCT01147666 · fetched Nov 12, 2026
Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring DialysisPHASE2 · COMPLETED · started Nov 1, 2006ClinicalTrials.gov NCT00761657 · fetched Nov 12, 2026
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary FibrosisPHASE1 · COMPLETED · started Dec 8, 2003ClinicalTrials.gov NCT00074698 · fetched Nov 12, 2026

SEC filings12

8-K · 8-KSEC EDGAR · filed Oct 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 1, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 31, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 16, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 9, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 11, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 9, 2026 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026